The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to asciminib for the treatment of adults with newly diagnosed Philadelphia ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage ...

Findings showed 30% of patients in the ponatinib arm achieved MRD-negative complete response rate at the end of the induction phase vs 12% of those in the imatinib arm. The Food and Drug ...

(RTTNews) - Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia ...

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Bosutinib Tablets, 400 mg. The ...

Bosutinib approved for chronic myelogenous leukemia The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – ...

HOUSTON ― According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) ...